FrancophonIA/ELRC3.0 huggingface dataset:
English: Tazocin® 4 g/ 500 mg 4 g/500mg
Estonian: Tazocin® 4 g/ 500 mg 4 g /500 mg Süstelahuse pulber
English: Sodium piperacillin and sodium tazobactam, equivalent to 2 g piperacillin and 250 mg tazobactam.
Estonian: Piperatsilliinnaatrium ja tasobaktaamnaatrium, mis on ekvivalentne 2 g piperatsilliiniga ja 250 mg tasobaktaamiga
English: Intravenous use 2 g piperacillinum / 0,25 g tazobactamum
Estonian: 2 g piperatsilliini/ 0,25 g tasobaktaami
English: 0.5366 g tazobactam sodium equivalent to 0.500 g tazobactam and 4.170 g piperacillin sodium equivalent to 4.00 g piperacillin
Estonian: 0,5366 g tasobaktaamnaatriumi, mis on ekvivalentne 0,500 g tasobaktaamiga ja 4,170 g piperatsilliinnaatriumi, mis on ekvivalentne 4,00 g piperatsilliiniga.
English: Piperacillin 2g and tazobactam250mg both present as sodium salts.
Estonian: Piperatsilliini 2 g ja tasobaktaami 250 mg, mõlemad naatriumisoolana.
English: 4 g piperacillin (in form of piperacillin sodium) and 0,5 g tazobactam (in form of tazobactam sodium).
Estonian: 4 g piperatsilliini (piperatsilliinnaatriumina) ja 0,5 g tasobaktaami (tasobaktaamnaatriumina).
English: 2.25 G/VIAL
Estonian: 2.25 G/VIAL Süstelahuse pulber
English: 2000mg + 250 mg
Estonian: 2000 mg + 250 mg Süstelahuse pulber
English: 2 g piperacillin (in form of piperacillin sodium) and 0,25 g tazobactam (in form of tazobactam sodium).
Estonian: 2 g piperatsilliini (piperatsilliinnaatriumina) ja 0,25 g tasobaktaami (tasobaktaamnaatriumina).
English: 2g piperacillin and 0.25g tazobactam (both present as sodium salts).
Estonian: 2 g piperatsilliini ja 0,25 g tasobaktaami (mõlemad naatriumisoolana).
English: Sodium piperacillin 2.085 g sodium tazobactam 268.300 mg
Estonian: 2 g/250 mg Infusioonilahuse pulber Intravenoosne piperatsilliinnaatriumi 2.085 g tasobaktaamnaatriumi 268.300 mg
English: 4.5 G/VIAL
Estonian: 4.5 G/VIAL Süstelahuse pulber
English: Sodium piperacillin 4.170 g sodium tazobactam 536.600 mg
Estonian: 4,170 g piperatsilliinnaatriumi, 536,600 mg tasobaktaamnaatriumi
English: 4g piperacillin and 0.5g tazobactam (both present as sodium salts).
Estonian: 4 g piperatsilliini ja 0,5 g tasobaktaami (mõlemad naatriumisoolana).
English: 2.085 g sodium piperacillin equivalent to 2 g piperacillin and 0.2683 g sodium tazobactam equivalent to 0.250 g tazobactam.
Estonian: 2,085 g piperatsilliinnaatriumi, mis on ekvivalentne 2 g piperatsilliiniga ja 0,2683 g tasobaktaamnaatriumi, mis on ekvivalentne 0,250 g tasobaktaamiga
English: Piperacillin sodium corresponding to piperacillin 2 g and tazobactam sodium corresponding to tazobactam 0,25 g
Estonian: Piperatsilliinnaatrium, mis vastab 2 g piperatsilliinile ja tasobaktaamnaatrium, mis vastab 0,25 g tasobaktaamile
English: Burgos, Km 23 - Desvío Algete Km 1
Estonian: Storchengasse 1
English: 2.085 g of piperacillin sodium equivalent to 2 g of piperacillin and 0.2683 g of tazobactam sodium equivalent to 250 mg of tazobactam
Estonian: 2,085 g piperatsilliinnaatriumi, mis on ekvivalentne 2 g piperatsilliiniga ja 0,2683 g tasobaktaamnaatriumi, mis on ekvivalentne 250 mg tasobaktaamiga
English: Tazocin® 2 g/ 250 mg 2g /250 mg Powder for solution for injection
Estonian: Tazocin 2g/250 mg poudre pour solution injectable 2 g/250 mg Süstelahuse pulber
English: Piperacillin (in the form of piperacillin sodium) 4 g Tazobactam (in the form of tazobactam sodium) 0.50 g
Estonian: 4 g piperatsilliini (piperatsilliinnaatriumina) 0,50 g tasobaktaami (tasobaktaamnaatriumina)
English: 4g+0.500 g Powder for solution for infusion
Estonian: 4 g+0.500 g Infusioonilahuse pulber Intravenoosne
English: TAZOCIN 2g/0.25g contains 2 active ingredients; piperacillin 2g and tazobactam 0.25g both present as sodium salts.
Estonian: TAZOCIN 2 g/0,25 g sisaldab 2 toimeainet;
English: 1 injection vial contains piperacillin sodium equivalent to 4.0g of piperacillin and tazobactam sodium equivalent to 0.5g of tazobactam.
Estonian: Piperatsilliinnaatrium, mis vastab 4 g piperatsilliinile ja tasobaktaamnaatrium, mis vastab 0,5 g tasobaktaamile
English: 4.17 g sodium piperacillin equivalent to 4 g piperacillin and 0.5366 g sodium tazobactam equivalent to 0.5 g tazobactam.
Estonian: 4,17 g piperatsilliinnaatriumi, mis on ekvivalentne 4 g piperatsilliiniga ja 0,5366 g tasobaktaamnaatriumi, mis on ekvivalentne 0,5 g tasobaktaamiga
English: 4,170 g piperacillin sodium equivalent to 4000 mg of piperacillin and 0.5366 g tazobactam sodium equivalent to 500 mg of tazobactam.
Estonian: 4,170 g piperatsilliinnaatriumi, mis on ekvivalentne 4000 mg piperatsilliiniga ja 0,5366 g tasobaktaamnaatriumi, mis on ekvivalentne 500 mg tasobaktaamiga.
English: Tazonam 4,0 g/0,5 g
Estonian: Tazonam 4,0 g/0,5 gTrockenstechampullen
English: 4000m g+500mg g
Estonian: 4000 mg + 500 mg Süstelahuse pulber
English: 4 g piperacillin equivalent to 4.17 g piperacillin sodium
Estonian: 4170 mg piperatsilliinnaatriumi, mis on ekvivalentne 4 g piperatsilliiniga
English: 0.5 g tazobactam equivalent to 0.5366 g tazobactam sodium
Estonian: 4,170 g piperatsilliinnaatriumi 0,5366 g tasobaktaamnaatriumi
English: Piperacillin (in the form of piperacillin sodium) 2 g Tazobactam (in the form of tazobactam sodium) 0.25 g
Estonian: 2 g piperatsilliini (piperatsilliinnaatriumina) 0,25 g tasobaktaami (tasobaktaamnaatriumina)
English: 4.170 g piperacillin sodium equivalent to 4 g piperacillin and 0.5366 g tazobactam sodium equivalent to 500 mg tazobactam.
Estonian: 4,170 g piperatsilliinnaatriumi, mis on ekvivalentne 4 g piperatsilliiniga ja 0,5366 g tasobaktaamnaatriumi, mis on ekvivalentne 500 mg tasobaktaamiga
English: Trockenstechampullen 4,0 g/0,5 g Lyophilisate for solution for injection or infusion
Estonian: 4,0 g/0,5 g Süstelahuse lüofilisaat/ Infusioonilahuse lüofilisaat
English: 2g/250 mg
Estonian: Tazocin® 2 g/ 250 mg 2 g /250 mg
English: 2g/250 mg Powder for Solution for Injection or Infusion
Estonian: 2 g/250 mg Süste- või infusioonilahuse pulber
English: What measures are being taken to ensure the safe and effective use of Ivemend?
Estonian: Mis meetmed võetakse, et tagada Ivemendi ohutu ja efektiivne kasutamine?
English: Further information on Ivemend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Ivemendi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports
English: What is Ivemend and what is it used for?
Estonian: Mis on Ivemend ja milleks seda kasutatakse?
English: This overview was last updated in 05-2018.
Estonian: Kokkuvõtte viimane uuendus: 05.2018.
English: Ivemend received a marketing authorisation valid throughout the EU on 11 January 2008.
Estonian: Ivemend on saanud müügiloa, mis kehtib kogu ELis, 11. jaanuaril 2008.
English: The European Medicines Agency therefore decided that Ivemend's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas seepärast, et Ivemendi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Aprepitant is a neurokinin 1 (NK1) receptor antagonist.
Estonian: Aprepitant on neurokiniin-1 (NK1) retseptorite antagonist.
English: As for all medicines, data on the use of Ivemend are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Ivemendi kasutamise kohta pidevat järelevalvet.
English: What are the risks associated with Ivemend?
Estonian: Mis riskid Ivemendiga kaasnevad?
English: When substance P attaches to these receptors, it causes nausea and vomiting.
Estonian: Kui P-aine seondub nende retseptoritega, põhjustab see iiveldust ja oksendamist.
English: Around 72% of patients treated with either medicine did not have any nausea or vomiting over the five days after receiving chemotherapy.
Estonian: Ligikaudu 72%-l kummagi ravimiga ravitud patsientidest ei esinenud viie päeva jooksul pärast keemiaravi iiveldust ega oksendamist.
English: In children it may be given on the first day or on multiple days through a tube inserted into a large vein near the heart.
Estonian: Lastele võidakse seda manustada esimesel või mitmel päeval kateetri kaudu, mis on viidud suurde veeni südame lähedal.
English: Aprepitant has been authorised in the European Union (EU) as Emend since 2003.
Estonian: Aprepitant on ravimina Emend ELis heaks kiidetud alates 2003. aastast.
English: For more information about using Ivemend, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Ivemendi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Other information about Ivemend
Estonian: Muu teave Ivemendi kohta
English: Side effects reported with Ivemend are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ivemendi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivemend have been included in the summary of product characteristics and the package leaflet.
Estonian: Ivemendi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This means that it is converted to aprepitant in the body.
Estonian: See tähendab, et ravim muundub organismis aprepitandiks.
English: In adults, Ivemend is given as a slow infusion into a vein on the first day of chemotherapy.
Estonian: Täiskasvanutele manustatakse Ivemendi aeglase veeniinfusioonina esimesel keemiaravi päeval.
English: The most common side effects with Ivemend (seen in between 1 and 10 patients in 100) are increased liver enzymes, headache, hiccups, constipation, dyspepsia (heartburn), loss of appetite and fatigue (weakness or tiredness).
Estonian: Ivemendi kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on maksaensüümide aktiivsuse suurenemine, peavalu, luksumine, kõhukinnisus, düspepsia (kõrvetised), isutus ja väsimus.
English: It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.
Estonian: Seda kasutatakse täiskasvanutel ja vähemalt 6-kuustel lastel, kes saavad teadaolevalt mõõdukat või tugevat iiveldust ja oksendamist põhjustavat keemiaravi.
English: What benefits of Ivemend have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ivemendi kasulikkus?
English: Ivemend must always be given together with other medicines that prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist' (such as ondansetron).
Estonian: Ivemendi peab alati manustama koos teiste iiveldust ja oksendamist ennetavate ravimitega, sealhulgas kortikosteroid (näiteks deksametasoon) ja 5-HT3 antagonist (näiteks ondansetroon).
English: It stops a chemical in the body called ‘substance P' from attaching to the NK1 receptors.
Estonian: See takistab organismis teatud kemikaali (P-aine) seondumist NK1-retseptoritega.
English: By blocking these receptors, Ivemend can prevent nausea and vomiting, which often happens during and after chemotherapy.
Estonian: Nende retseptorite blokeerimisega aitab Ivemend ennetada keemiaravi ajal ja järel sageli esinevat iiveldust ja oksendamist.
English: A main study showed that Ivemend was as effective as Emend at preventing nausea and vomiting in patients undergoing chemotherapy and its side effects are considered to be manageable.
Estonian: Põhiuuringus tõendati, et Ivemend oli keemiaravi patsientidel iivelduse ja oksendamise ennetamisel sama efektiivne kui Emend, ning selle kõrvalnähte peetakse hallatavaks.
English: It contains the active substance fosaprepitant.
Estonian: Ravim sisaldab toimeainena fosaprepitanti.
English: Ivemend must not be used at the same time as pimozide (used to treat mental illness), terfenadine and astemizole (used to treat allergy symptoms) and cisapride (used to relieve certain stomach problems).
Estonian: Ivemendi ei tohi kasutada samaaegselt pimosiidi (psüühikahäirete ravim), terfenadiini ja astemisooli (allergiasümptomite ravim) ega tsisapriidiga (teatud maoprobleemide ravim).
English: A main study in 2,000 patients with cancer showed that Ivemend was as effective as a Emend another medicine approved for preventing nausea and vomiting.
Estonian: Põhiuuringus, milles osales 2000 vähipatsienti, oli Ivemend sama efektiivne kui Emend (teine iivelduse ja oksendamise ennetamiseks heaks kiidetud ravim).
English: An overview of Ivemend and why it is authorised in the EU
Estonian: Ülevaade ravimist Ivemend ja ELis müügiloa väljastamise põhjendus
English: Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.
Estonian: Ivemend on ravim, mida kasutatakse keemiaravi ravimitest (vähiravimid) põhjustatud iivelduse ja oksendamise ennetamiseks.
English: For the full list of side effects reported with Ivemend, see the package leaflet.
Estonian: Ivemendi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How is Ivemend used?
Estonian: Kuidas Ivemend toimib?
English: How does Ivemend work?
Estonian: Kuidas Ivemendi kasutatakse?
English: The active substance in Ivemend, fosaprepitant, is a ‘prodrug' of aprepitant.
Estonian: Ivemendi toimeaine fosaprepitant on aprepitandi eelravim.
English: _ _ 1 Whole virion non-adjuvanted influenza vaccine, inactivated, containing antigen of *: A/Vietnam/1203/2004 (H5N1) 7.5 micrograms** per 0.5 ml dose * propagated in Vero cells (continuous cell line of mammalian origin) ** expressed in micrograms hemagglutinin
Estonian: _ _ 1 Kogu viriooni mitteadjuvantne gripi vaktsiin, inaktiveeritud, sisaldab järgmist antigeeni *: /Vietnam/1203/2004 (H5N1) 7,5 mikrogrammi** 0,5 ml kohta * kultiveeritud Vero rakukultuuril (imetajatelt pärinev pidev rakuliin) ** väljendatud hemaglutiniini mikrogrammides
English: 20 vials
Estonian: 20 viaali
English: Immediate Packaging Content (concentration)
Estonian: Pakendi sisu (kontsentratsioon)
English: MA (EU) Number (Invented) name
Estonian: (Väljamõeldud) nimetus
English: 1 syringe
Estonian: 1 eeltäidetud süstal
English: Single-dose prefilled syringe (glass) without needle
Estonian: Süste-suspensioon Intramuskulaarne Ühekordse annusega eeltäidetud süstal (klaas) ilma nõelata
English: Pack size multi-dose vial (glass)
Estonian: Süste-suspensioon Intramuskulaarne Mitut annust sisaldav viaal (klaas)
English: Route of Administration
Estonian: Pakendi suurus
English: Telzir (fosamprenavir)
Estonian: Telzir (fosamprenaviir)
English: Telzir received a marketing authorisation valid throughout the EU on 12 July 2004.
Estonian: Telzir on saanud müügiloa, mis kehtib kogu ELis, 12. juulil 2004.
English: Further information on Telzir can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Telzir.
Estonian: Lisateave Telziri kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Telzir.
English: What measures are being taken to ensure the safe and effective use of Telzir?
Estonian: Mis meetmed võetakse, et tagada Telziri ohutu ja efektiivne kasutamine?
English: A similar benefit was also seen in one main study including 57 children aged between 2 and 18 years.
Estonian: Sarnast kasulikkust täheldati ka ühes põhiuuringus, milles osales 57 last vanuses 2-18 eluaastat.
English: This overview was last updated in 05-2019.
Estonian: Kokkuvõtte viimane uuendus: 05.2019.
English: Telzir has been studied in three main studies involving 1,862 adults.
Estonian: Telziri kasutamist uuriti kolmes põhiuuringus, milles osales 1862 täiskasvanut.
English: Telzir tablets can be taken with or without food.
Estonian: Telziri tablette tohib võtta koos toiduga või ilma.
English: As for all medicines, data on the use of Telzir are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Telziri kasutamise kohta pidevat järelevalvet.
English: Similar side effects are seen in younger patients.
Estonian: Nooremate patsientide kõrvalnähud on samalaadsed.
English: What is Telzir and what is it used for?
Estonian: Mis on Telzir ja milleks seda kasutatakse?
English: Telzir is available as tablets (700 mg) and as an oral suspension (50 mg/ml) to be taken by mouth.
Estonian: Telzirit turustatakse tablettidena (700 mg) ning suukaudse suspensioonina (50 mg/ml).
English: However, there were too few patients aged below 6 years to support the use of Telzir in this age group.
Estonian: Siiski ei olnud uuringus alla 6-aastasi patsiente piisavalt, et toetada Telziri kasutamist selles vanuserühmas.
English: In adults, each dose of Telzir must be given with 100 mg ritonavir, twice a day.
Estonian: Täiskasvanutel tuleb iga Telziri annus manustada koos 100 mg ritonaviiriga, kaks korda ööpäevas.
English: Why is Telzir authorised in the EU?
Estonian: Miks Telzir ELis heaks kiideti?
English: As Telzir is converted into amprenavir in the body, it must not be given at the same time as other medicines containing amprenavir.
Estonian: Et Telzir muundub organismis amprenaviiriks, ei tohi seda manustada samal ajal teiste amprenaviiri sisaldavate ravimitega.
English: Telzir does not cure HIV infection or AIDS, but it can hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Telzir ei ravi HIV-nakkust ega AIDS-i välja, kuid võib immuunsüsteemi kahjustumist ning AIDS-iga seotud nakkuste ja haiguste teket edasi lükata.
English: Other information about Telzir:
Estonian: Muu teave Telziri kohta
English: Side effects reported with Telzir are carefully evaluated and any necessary action taken to protect patients.
Estonian: Telziri kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: It slows down the rate at which amprenavir is broken down, helping to increase levels of amprenavir in the blood.
Estonian: See aeglustab amprenaviiri lagunemist, aidates suurendada amprenaviiri sisaldust veres.
English: Telzir is used in combination with ritonavir and other HIV medicines.
Estonian: Telzirit kasutatakse koos ritonaviiriga ja teiste HIV-ravimitega.
English: Treatment with Telzir should be started by a doctor who has experience in the management of HIV infection.
Estonian: Ravi Telziriga peab alustama HIV-nakkuse ravis kogenud arst.
English: For more information about using Telzir, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Telzir have been included in the summary of product characteristics and the package leaflet.
Estonian: Telziri ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Telzir must not be used in patients who are taking lurasidone (for schizophrenia and bipolar disorder), paritaprevir (for hepatitis C), simvastatin or lovastatin (for lowering blood cholesterol), rifampicin (for tuberculosis), St John's wort (a herbal preparation for depression and anxiety), or certain medicines that are broken down in the same way as Telzir or ritonavir as Telzir may affect their blood levels.
Estonian: Telzirit ei tohi kasutada patsiendid, kes kasutavad lurasidooni (skisofreenia ja bipolaarse häire ravim), paritapreviiri (C-hepatiidi ravim), simvastatiini või lovastatiini (vere kolesteroolisisaldust vähendav ravim), rifampitsiini (tuberkuloosiravim), naistepuna (taimne depressiooni- ja ärevusravim) või ravimeid, mis lagunevad samal viisil kui Telzir või ritonaviir, sest Telzir võib mõjutada nende ravimite sisaldust veres.
English: When the enzyme is blocked, the virus does not reproduce normally, slowing down the spread of infection.
Estonian: Kui ensüüm on blokeeritud, on viiruse normaalne paljunemine häiritud ning infektsiooni levik organismis aeglustub.
English: The recommended dose for adults (aged 18 years or over) and for patients aged between 6 and 18 years who weigh more than 39 kg is 700 mg twice a day.
Estonian: Telziri soovitatav annus täiskasvanutele (vähemalt 18-aastased) ja üle 39 kg kaaluvatele 6-18-aastastele patsientidele on 700 mg kaks korda ööpäevas.
English: Although the Agency noted that the use of ritonavir-boosted Telzir had not been studied sufficiently in heavily pretreated patients and that studies carried out in children did not compare Telzir with a comparator medicine, it decided that Telzir's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Kuigi Euroopa Ravimiamet märkis, et ritonaviiriga võimendatud Telziri mõju varem intensiivselt ravitud patsientidel ei ole piisavalt uuritud ja et lastel ei ole tehtud võrdlevaid uuringuid, otsustas amet, et Telziri kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Telzir, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: Koos teiste viirusvastaste ravimitega manustatav Telzir vähendab HIV-i kogust veres ja hoiab selle sisalduse väikese.
English: It contains the active substance fosamprenavir.
Estonian: Ravim sisaldab toimeainena fosamprenaviiri.
English: What are the risks associated with Telzir?
Estonian: Mis riskid Telziriga kaasnevad?
English: In one study, after 48 weeks of treatment, 69% of previously untreated adults taking ritonavir-boosted Telzir (221 out of 322) and 68% of those taking nelfinavir (221 out of 327) had viral loads below 400 copies/ml (considered a low viral load).
Estonian: Ühes uuringus oli pärast 48-nädalast ravi varem ravimata täiskasvanud patsiente, kelle viiruskoormus oli alla 400 koopia/ml, ritonaviiriga võimendatud Telziri uuringurühmas 69% (221 patsienti 322st) ja nelfinaviiri uuringurühmas 68% (221 patsienti 327st).
English: Two of the studies in previously untreated patients showed that Telzir in combination with other antiviral medicines was as effective as comparator medicines.
Estonian: Kaks uuringut varem ravimata patsientidel näitasid, et koos teiste viirusvastaste ravimitega manustatav Telzir oli sama efektiivne kui võrdlusravimid.
English: How does Telzir work?
Estonian: Kuidas Telzir toimib?
English: Similar results were seen in the other study comparing ritonavir-boosted Telzir with ritonavir-boosted lopinavir, with around three-quarters of both groups of previously untreated patients having viral loads below 400 copies/ml.
Estonian: Sarnased tulemused saadi ka teises uuringus, milles ritonaviiriga võimendatud Telziri võrreldi ritonaviiriga võimendatud lopinaviiriga ning milles ligikaudu kolmveerandil varem ravimata patsientidest mõlemas rühmas oli viiruskoormus alla 400 koopia/ml.
English: In a third study in patients who had been treated before, Telzir was less effective than the comparator medicine lopinavir, with patients taking lopinavir having larger reductions in viral loads over the first 48 weeks.
Estonian: Kolmandas uuringus oli Telzir varem ravitud patsientidel vähem efektiivne kui võrdlusravim lopinaviir ning lopinaviiri kasutanud patsientidel vähenes viiruskoormus kõige rohkem esimese 48 nädala jooksul.
English: The oral suspension should be taken without food in adults, but in younger patients it should be taken with food in order to hide the taste and help them stick to treatment.
Estonian: Täiskasvanutele manustatakse Telziri suukaudset suspensiooni ilma toiduta, noorematele patsientidele aga koos toiduga, et varjata maitset ja soodustada raviskeemi järgimist.
English: The most common side effects in adults taking Telzir (seen in more than 1 patient in 10) are diarrhoea and increases in the levels of cholesterol (a type of fat) in the blood.
Estonian: Telziri kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on kõhulahtisus ja kolesterooli (teatud rasva) sisalduse suurenemine veres.
English: In patients aged between 6 and 18 years who weigh between 25 and 39 kg, the dose depends on body weight.
Estonian: 25-39 kg kaaluvate 6-18-aastaste patsientide annus sõltub kehamassist.